Differential Prognosis of Mcrc Patients Post-Progression to First Line Triplet Chemotherapy/Bevacizumab, Fir-B/Fox, According to Second Line Treatment and Kras Genotype

Authors :: Corrado Ficorella
Enrico Ricevuto
Katia Cannita
Gemma Bruera
Aldo Victor Giordano
Roberto Vicentini
Source :: Annals of Oncology. 24:iv91
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: Oncology
medicine.medical_specialty
Second line treatment
Bevacizumab
business.industry
First line
Hematology
medicine.disease_cause
Chemotherapy regimen
Internal medicine
Triplet chemotherapy
Genotype
medicine
KRAS
business
medicine.drug

Tools